Annexon, Inc. (ANNX)
Automate Your Wheel Strategy on ANNX
With Tiblio's Option Bot, you can configure your own wheel strategy including ANNX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ANNX
- Rev/Share 0.0
- Book/Share 1.646
- PB 1.2394
- Debt/Equity 0.1161
- CurrentRatio 7.9936
- ROIC -0.6722
- MktCap 223816560.0
- FreeCF/Share -0.9445
- PFCF -1.6
- PE -1.8051
- Debt/Assets 0.0934
- DivYield 0
- ROE -0.5445
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission
Read More
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
BRISBANE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.
Read More
About Annexon, Inc. (ANNX)
- IPO Date 2020-07-24
- Website https://www.annexonbio.com
- Industry Biotechnology
- CEO Mr. Douglas E. Love Esq., J.D.
- Employees 106